Key points from article :
Cellino Biotech, a leader in regenerative medicine, has secured up to $25 million in funding from the US Government's Advanced Research Projects Agency for Health (ARPA-H). This investment will help Cellino advance its innovative biomanufacturing technology, designed to produce personalized regenerative medicines using stem cells. These therapies have the potential to treat, prevent, and even reverse a range of diseases, but large-scale production has been limited due to manual processes, variability, and high costs. Cellino aims to overcome these challenges by combining AI and laser technology to automate the production process, making therapies more scalable and affordable.
The funding will support the development of a cassette-based system to scale the production of induced pluripotent stem cells (iPSCs), which can be tailored to individual patients. This approach not only reduces production costs but also minimizes immune-related complications, as therapies are created from a patient’s own cells. The NEBULA project, backed by ARPA-H, aims to expedite the availability of these personalized treatments in hospitals across the U.S.
Cellino’s biomanufacturing platform could lead to groundbreaking treatments for chronic conditions like Parkinson’s, diabetes, and heart disease. By automating and scaling the production of regenerative cells, the company hopes to make these therapies more accessible, revolutionizing healthcare for millions of people.
